Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615359 | 0.89 | POLB (0.47) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL23041613 | 0.86 | POLB (0.46) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL19615958 | 0.86 | POLB (0.46) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL7218733 | 0.85 | ALDH1A1 (0.45) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL19635528 | 0.79 | POLB (0.47) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL5560879 | 0.78 | CYP1A2 (0.46) | POLBKDM4EGAAKMT2A | |
| SCHEMBL19635510 | 0.78 | POLB (0.47) | POLBRXFP1RAD52UHRF1PIK3CA | |
| SCHEMBL22439702 | 0.77 | NR5A2 (0.48) | POLBPIK3CAALDH1A1KDM4EGAA | |
| SCHEMBL15441448 | 0.77 | TRPV4 (0.57) | POLBALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL23041539 | 0.77 | POLB (0.46) | POLBRXFP1RAD52UHRF1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653304-B2 | Antiarthritic agents; skin disorders; anticarcinogenic agents | BRISTOL-MYERS SQUIBB CO. | 2003-11-25 | — | — | US | disclosed |
| EP-1254115-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | Bristol-Myers Squibb Company (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | disclosed |
| WO-2001058869-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | CNR1, CNR2, GPR18 | POLB 3977/4885RXFP1 192/4885RAD52 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.